Evidence of pioneer factor activity of an oncogenic fusion transcription factor

• DOI: 10.1016/j.isci.2021.102867
• Publication Date: 2021-07-16T10:03:03Z
• Authors: Benjamin D. Sunkel; Meng Wang; Stephanie LaHaye; Benjamin J. Kelly; James R. Fitch; Frederic G. Barr; Peter White; Benjamin Z. Stanton
• Keywords: Reprogramming; CTCF; Pioneer factor

Recent characterizations of pioneer transcription factors provide insights into their structures and patterns chromatin recognition associated with roles in cell fate commitment transformation. Intersecting these basic science concepts, identification (PFs) fused together as driver translocations childhood cancers raises questions whether fusions retain the fundamental ability to invade repressed chromatin, consistent monomeric PF constituents. This study defines cellular localization PAX3-FOXO1, an oncogenic rhabdomyosarcoma (RMS), derived from a fusion PFs. To quantitatively define its chromatin-targeting functions capacity drive epigenetic reprogramming, we developed ChIP-seq workflow per-cell normalization (pc-ChIP-seq). Our quantitative studies address structural variation RMS genomes reveal inactive PAX3-FOXO1. Taken together, our are function for oncoprotein RMS, binding nucleosome-motif targeting.